Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 3,600
- Locations
- 1
- Primary Endpoint
- Rate of function independent
Study Overview
Brief Summary
Objective: To observe the practical application of the standardized green channel treatment system for stroke in Xi 'an in the real world. Methods: Clinical data and information of patients with acute ischemic stroke who received standardized green channel treatment for stroke were collected, and a multicenter observational clinical study was carried out in the real world to evaluate the prognosis, mortality, incidence of asymptomatic and symptomatic cerebral hemorrhage, incidence of pneumonia, and recurrence rate of stroke after 90 days.
Detailed Description
The standardized green channel treatment system for acute ischemic stroke includes: Triage nurse triage timely, rapid assessment emergency doctor, suspected stroke the green channel, immediately start in the green channel of stroke accompanied by doctors and nurses stroke patients improve CT examination, intravenous thrombolysis or CT room, emergency room if considering large vascular lesions and the onset time in 6 hours, and rapidly to international for endovascular treatment, if the onset time of more than 6 hours, Rapid evaluation of ischemic penumbra and vascular occlusion by multi-mode imaging. If there are indications for endovascular treatment, go to the cath room for endovascular treatment as soon as possible.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 100 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 years old;
- •Consistent with the diagnosis of acute ischemic stroke;
- •24 hours from onset to enrollment;
- •Informed consent
Exclusion Criteria
- •Patients who refuse to receive intravenous thrombolysis or intravascular intervention (including intravascular mechanical thrombolysis and arterial thrombolysis);
- •Stroke patients caused by brain tumor, brain trauma and blood diseases;
- •Those with a history of stroke and sequelae affecting the outcome assessment, namely, mRS 2 points before the onset of this stroke;
- •Combined with claudication osteoarthritis rheumatoid arthritis gout arthritis and other limb dysfunction and affect the neurological function examination;
- •Patients with severe hepatic and renal insufficiency (Note: Hepatic insufficiency refers to ALT or AST values greater than 2 times the upper normal limit; Renal insufficiency refers to blood creatinine value greater than 2 times the normal upper limit);
- •Suffering from other serious life-threatening diseases with an expected survival time of less than 3 months;
- •Other diseases that limit neurological function evaluation or affect patient follow-up;
- •A woman planning to be pregnant or breastfeeding;
- •Currently participating in other clinical trials;
- •Refuse to participate in the registration of investigators
Outcomes
Primary Outcomes
Rate of function independent
Time Frame: 90 days after onset
Rate of modified Rankin Scale(mRS) score less than 3 at 90 days
Secondary Outcomes
- Rate of mortality(90 days after onset)
- Rate of stroke recurrence(90 days after onset)
- Rate of cerebral hemorrhage and pneumonia(During hospitalization.)